HR
ENTA icon

Howe & Rusling’s Enanta Pharmaceuticals ENTA Stock Holding History

Howe & Rusling’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-30
Closed -$1K – 1012
2015
Q3 		$1K Hold
30
– – ﹤0.01% 909
2015
Q2 		$1K Buy
+30
New +$1.17K ﹤0.01% 949

Other funds holding ENTA

ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Howe & Rusling's ENTA Position: Q4 2015 in Review

Howe & Rusling sold out of Enanta Pharmaceuticals (ENTA) in Q4 2015, closing a stake of 30 shares — an estimated $1K sold.

Howe & Rusling first reported a position in ENTA in Q2 2015 and held it in 2 quarters. The position peaked at $1K in Q3 2015. 136 funds tracked by Wall St. Rank hold ENTA as of Q4 2015.

  • Howe & Rusling reported no remaining Enanta Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Howe & Rusling sold 30 Enanta Pharmaceuticals shares in Q4 2015, an estimated $1K.
  • Howe & Rusling first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Howe & Rusling's Enanta Pharmaceuticals position peaked at $1K in Q3 2015.
  • 136 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2015.

Based on Howe & Rusling's 13F filing for Q4 2015, filed 11 Feb 2016.